Copyright
©The Author(s) 2023.
World J Diabetes. Apr 15, 2023; 14(4): 396-411
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.396
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.396
Drug molecule | Mean weight reduction in kg (95%CI) | Mean % HbA1c reduction (95%CI) | Follow-up period (yr) |
Exenatide (weekly) | -1.27 (-1.4 to -1.13) | -0.53 (-0.57 to -0.50) | 3.2 |
Liraglutide | -2.3 (-2.5 to -2.0) | -0.40 (-0.45 to -0.34) | 3.8 |
Lixisenatide | -0.7 (-0.9 to -0.5) | -0.27 (-0.31 to -0.22) | 2.1 |
Albiglutide | -0.83 (-1.06 to -0.60) | -0.52 (-0.58 to -0.45) | 1.5 |
Dulaglutide | -1.46 (-1.67 to -1.25) | -0.61 (-0.65 to -0.58) | 5.4 |
Semaglutide | -2.87 (-3.47 to –2.28) for 0.5 mg | -0.66 (-0.80 to – 0.52) for 0.5 mg | 2.0 |
-4.5 (-4.94 to -3.75) for 1 mg | -1.05 (-1.19 to -0.91) for 1 mg |
Ref. | Drug molecule | Mean weight reduction in kg (SE/95%CI) | Mean % haemoglobin reduction (95%CI) | Follow-up |
Neal et al[104], 2017 (CANVAS) | Canagliflozin | -1.60 (- 1.70 to -1.51) | -0.58 (-0.61 to -0.56) | 3.5 yr |
Wiviott et al[105], 2019 (DECLARE) | Dapagliflozin | -1.80 (-2.00 to -1.70) | -0.42 (-0.45 to -0.40) | 4.2 yr |
Häring et al[106], 2014 (EMPA-REG) | Empagliflozin | -1.63 (-2.11 to -1.5) for 10 mg | -0.57 (-0.70 to -0.43) for 10 mg | 24 wk |
-2.01 (-2.49 to -1.53) for 25 mg | -0.64 (-0.77 to -0.50) for 25 mg | |||
Rosenstock et al[107], 2018 (VERTIS-MET) | Ertugliflozin | -3.00 (-3.30 to -2.70) for 5 mg | -0.70 (-0.90 to -0.50) for 5 mg | 24 wk |
-2.90 (-3.20 to -2.60) for 15 mg | -0.90 (-1.00 to -0.70) for 15 mg | |||
Dagogo-Jack et al[108], 2018 (VERTIS-SITA) | Ertugliflozin | -2.0 (-2.7 to -1.4) for 5 mg | -0.70 (-0.90 to -0.50) for 5 mg | 26 wk |
-1.7 (-2.4 to -1.1) for 10 mg | -0.80 (-0.90 to -0.60) for 10 mg |
- Citation: Michaelidou M, Pappachan JM, Jeeyavudeen MS. Management of diabesity: Current concepts. World J Diabetes 2023; 14(4): 396-411
- URL: https://www.wjgnet.com/1948-9358/full/v14/i4/396.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i4.396